You are here

  • Home
  • Archive
  • Volume 76, Issue 10
  • Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Cohen S, Genovese MC, Choy E, et al
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Annals of the Rheumatic Diseases 2017;76:1679-1687.